PDSB Stock Forecast & Price Target

PDS Biotechnology is viewed favorably because the Nant-led up to $22.55M PIPE materially strengthens liquidity after 2Q26 cash of $5.6M, reduces the funding overhang, and supports a sharper capital allocation toward PDS0301 while also preserving optionality for PDS0101 through a potential partner. The investment case is further reinforced by encouraging early PDS0301 data in MSS/pMMR colorectal liver metastases, where responses improved to 71.4% at six months in 22 patients and ~80% survival was seen at 24 months versus about 35% in the sequential comparator cohort. Those signals, together with immune activation findings and a planned roughly 90-patient randomized Phase 2b study, suggest a plausible path to broader clinical and commercial value if efficacy is confirmed without requiring HAIP.

PDS Biotechnology is viewed negatively because its turnaround hinges on PDS0301 while the company remains financially fragile, ending 2Q26 with just $5.6M in cash and facing about $15M to fund the randomized mCRC study through interim analysis plus another $15M for operations. The 36% workforce reduction, $842K restructuring charge in 3Q26, and COO departure underscore pressure to preserve capital rather than a position of strength, even as R&D and G&A are reduced for the remainder of 2026 and 2027. With PDS0101 pushed toward external partnership, and downside risks from failed clinical trials, inadequate funding, and substantial dilution still central, the outlook stays weak despite some encouraging early clinical data.